Santarus, Inc. (NASDAQ: SNTS) today announced the completion of a
secondary underwritten public offering of 4,887,500 shares of its common
stock, including 637,500 shares sold pursuant to the full exercise of an
option to purchase additional shares previously granted to the
underwriter. All shares were offered by Cosmo Technologies Limited at a
price to the public of $18.25 per share. Santarus did not sell any
shares and will not receive any proceeds from the offering.
Jefferies LLC acted as the sole book-running manager for the offering.
A shelf registration statement (including a prospectus) relating to
these securities was filed by Santarus with the Securities and Exchange
Commission (SEC) and declared effective by the SEC on April 29, 2009. A
final prospectus supplement and the accompanying prospectus related to
the offering have been filed with the SEC and are available on the SEC's
website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may also be obtained from Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 12th floor, New York, NY 10022 or by telephone at 877-547-6340
or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by physician specialists. The
company's current commercial efforts are focused on five products. UCERIS?(budesonide) extended release tablets for the induction of
remission in patients with active, mild to moderate ulcerative colitis
(omeprazole/sodium bicarbonate) for the treatment of certain upper
gastrointestinal disorders are promoted to gastroenterologists. GLUMETZA®
(metformin hydrochloride extended release tablets) and CYCLOSET®
(bromocriptine mesylate) tablets, which are indicated as adjuncts to
diet and exercise to improve glycemic control in adults with type 2
diabetes, and FENOGLIDE®
(fenofibrate) tablets, which is indicated as an adjunct to diet to
reduce high cholesterol, are promoted to endocrinologists and other
physicians who treat patients with type 2 diabetes. Full prescribing and
safety information for Santarus' products is available at www.santarus.com.
Santarus' product development pipeline includes the investigational drug
RUCONEST® (recombinant human C1 esterase inhibitor). A
Biologics License Application for RUCONEST was submitted to the FDA in
April 2013 for the treatment of acute angioedema attacks in patients
with hereditary angioedema. Santarus is also developing rifamycin SV MMX®,
which is in Phase III clinical testing for the treatment of travelers'
diarrhea. In addition, the company has completed a Phase I clinical
program with SAN-300, an investigational monoclonal antibody. More
information about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. The inclusion of forward-looking statements should not be
regarded as a representation by Santarus that any of its plans will be
achieved. Actual results may differ materially from those set forth in
this release due to risks and uncertainties inherent in Santarus'
business, including, without limitation, difficulties or delays in
development, testing, manufacturing and marketing of, and obtaining and
maintaining regulatory approvals for, Santarus' products and other risks
detailed in Santarus' prior press releases as well as in public periodic
filings with the SEC, including its Quarterly Report on Form 10-Q for
the quarter ended March 31, 2013.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as may be required by applicable law. This caution
is made under the safe harbor provisions of Section 21E of the Private
Securities Litigation Reform Act of 1995.
UCERIS?, and ZEGERID®
are trademarks of Santarus, Inc. GLUMETZA®
is a trademark of Biovail Laboratories International S.r.l. licensed
exclusively in the United States to Depomed, Inc. CYCLOSET®
is a trademark of VeroScience LLC. MMX®
is a trademark of Cosmo Technologies Limited. RUCONEST®
is a trademark of Pharming Group N.V.
Martha L. Hough, VP Finance & Investor
Debra P. Crawford, Chief
Stefan Loren, Ph.D. (firstname.lastname@example.org)
Robert Uhl (email@example.com)